Communiqués Edgewise Therapeutics, Inc.

Actions

EWTX

US28036F1057

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 25/09/2026			Varia. 5j.	Varia. 1 janv.
39,34 ^USD	-4,42%		-13,20%	+58,53%

25/09	Edgewise Therapeutics pourrait bénéficier du profil différencié de l’EDG-7500, selon Oppenheimer	MT
23/09	Le mécanisme d’EDG-7500 d’Edgewise inspire confiance, selon RBC	MT

Communiqués

02/09	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules	PR
24/08	Edgewise Therapeutics : Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026	PU
13/07	Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline	PR
01/04	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules	PR
10/03	Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up	PR
04/03	Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026	PR
03/03	Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference	PR
02/03	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules	PR
26/02	Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs	PR
05/02	Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026	PR
02/02	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules	PR
13/01	Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026	PR
06/01	Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026	PR
05/01	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules	PR
24/12	Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy	PR
02/12	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules	PR
20/11	Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors	PR
14/11	Edgewise Therapeutics : Initial Statement of Beneficial Ownership (Form 3)	PU
12/11	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules	PR
10/11	Edgewise Therapeutics : Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers	PU
07/11	Edgewise Therapeutics to Participate in Upcoming Investor Conferences	PR
06/11	Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights	PR
03/11	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules	PR
02/10/25	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules	PR
02/10/25	Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society	PR